Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice
Carmine Carbone(Agostino Gemelli University Polyclinic), Giampaolo Tortora(Università Cattolica del Sacro Cuore)
Cited by 6
Related Papers
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
|Journal for ImmunoTherapy of Cancer|2021|70
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling
|International Journal of Obesity|2017|40
Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
|British Journal of Cancer|2008|27
RETRACTED ARTICLE: Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer
|British Journal of Cancer|2013|25